Psychosocial Cancer Care Has Direct Ties to QOL, Emotional Well-Being

News
Video

Organizations such as ASCO and ESMO recognize the importance of integrating psychosocial care into cancer treatment.

The accessibility of psychosocial care correlates directly with the emotional well-being, quality of life, and treatment adherence of patients as they go through their cancer treatment, according to Cristiane Decat Bergerot, PhD, MS.

After the announcement of the first ever World Psycho-Oncology Day, CancerNetwork® spoke with Bergerot about the growing field of psycho-oncology and its importance in the current landscape of cancer care. As she said, a cancer diagnosis can lead to psychological distress and uncertainty, but proper care such as emotional support and counseling can mitigate those effects.

Over the years, the field has become more prominent and is now acknowledged by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), among other major organizations in oncology.

Bergerot is a psychologist, the head of supportive care at Grupo Oncoclínicas in Brazil, and a member of the International Psycho-Oncology Society.

Transcript:

Accessible psychosocial care is essential in cancer treatment because it directly impacts a patient’s emotional well-being, treatment adherence, and overall quality of life. We know that a cancer diagnosis brings significant psychological distress and uncertainty, which can affect decision-making and coping mechanisms. When psychosocial care is integrated into cancer care, patients receive the emotional support, counseling, and coping strategies needed to navigate treatment more effectively.

The growing body of research on psycho-oncology has significantly influenced clinical guidelines, treatment protocols, and research priorities in cancer care. We are now seeing many national [and] international oncology organizations, including ASCO and ESMO, emphasize the importance of integrating psychosocial care into standard cancer treatment. This has led to the inclusion of distress screenings in routine clinical assessments and recommendations for early palliative care involvement. Additionally, research on quality of life and patient-reported outcomes has shaped the development of more patient-centered treatment plans, ensuring that interventions address not just survival but also emotional and psychological well-being. As a result, cancer care is becoming increasingly multidisciplinary with psychosocial factors [and is] considered an [important] component of comprehensive treatment.

Reference

World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c

Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Related Content